Pharmacotherapy for smoking cessation in schizophrenia: a systematic review

References

• Mackowick KM, Lynch M-J, Weinberger AH, et al. Treatment of tobacco dependence in people with mental health and addictive disorders. Curr Psychiatry Rep. 2012;14(5):478–485.
   PubMed Web of Science ®Google Scholar
• Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: A population-based prevalence study. JAMA. 2000;284(20):2606–2610.
   PubMed Web of Science ®Google Scholar
• Williams JM, ZIEDONIS D, ABANYIE F, et al. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res. 2005;79(2–3):323–335.
   PubMed Web of Science ®Google Scholar
• Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45(3):204–206.
   PubMedGoogle Scholar
• de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull. 1996;22(3):405–409.
   PubMed Web of Science ®Google Scholar
• George TP. Cecil textbook of medicine: nicotine and tobacco (Chapter 32). Philadelphia, PA: Goldman L, Schafer AI; 2015.
   Google Scholar
• Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD007253.
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen CF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD000146.
   PubMed Web of Science ®Google Scholar
• Corelli RL, Hudmon KS. Medications for smoking cessation. West J Med. 2002;176(2):131–135.
   PubMedGoogle Scholar
• Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295(1):321–327.
   PubMed Web of Science ®Google Scholar
• Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3(1):45–53.
   PubMedGoogle Scholar
• Yousefi MK, Folsom TD, Fatemi SH. A review of varenicline’s efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. J Addict Res Ther. 2011;S4(1).
   Google Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474–3477.
   PubMed Web of Science ®Google Scholar
• Whitman GJ, Sheppard DG, Phelps MJ, et al. Breast cancer staging. Semin Roentgenol. 2006;41(2):91–104.
   PubMed Web of Science ®Google Scholar
• Wing VC, Wass CE, Soh DW, et al. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci. 2012;1248:89–106.
   PubMed Web of Science ®Google Scholar
• Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Jorenby DE, Brandon TH, et al. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction. 2010;105(11):2002–2013.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.
   Google Scholar
• Fatemi SH, Stary JM, Hatsukami DK, et al. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res. 2005;76(2–3):353–356.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835–1842.
   PubMed Web of Science ®Google Scholar
• Horst DW, Klein MW, Williams D, et al. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1(4):349–355.
   PubMedGoogle Scholar
• George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63(11):1092–1096.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380–386.
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170(12):1460–1467.
   PubMed Web of Science ®Google Scholar
• Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129(1):94–95.
   PubMed Web of Science ®Google Scholar
• Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):654–660.
   PubMed Web of Science ®Google Scholar
• Dutra SJ, Stoeckel LE, Carlini SV, et al. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl). 2012;219(1):25–34.
   PubMed Web of Science ®Google Scholar
• Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry. 2012;73(1):95–102.
   PubMed Web of Science ®Google Scholar
• Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218–225.
   PubMed Web of Science ®Google Scholar
• George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52(1):53–61.
   PubMed Web of Science ®Google Scholar
• Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3(4):397–403.
   PubMedGoogle Scholar
• Brody AL, Zorick T, Hubert R, et al. Combination extended smoking cessation treatment plus home visits for smokers with schizophrenia: a randomized controlled trial. Nicotine Tob Res. 2017;19(1):68–76.
   PubMed Web of Science ®Google Scholar
• Tulloch HE, Pipe AL, Els C, et al. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. BMC Med. 2016;14:80.
   PubMed Web of Science ®Google Scholar
• Metse AP, Wiggers J, Wye P, et al. Uptake of smoking cessation aids by smokers with a mental illness. J Behav Med. 2016;39(5):876–886.
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Garcia-Alvarez L, Saiz P, et al. Effectiveness of a multi-component smoking cessation support programme (McSCSP) for patients with severe mental disorders: study design. Int J Environ Res Public Health. 2013;11(1):373–389.
   PubMed Web of Science ®Google Scholar
• Pachas GN, Cather C, Pratt SI, et al. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J Dual Diagn. 2012;8(2):117–125.
   PubMed Web of Science ®Google Scholar
• Cather C, Hoeppner S, Pachas G, et al. Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy. J Dual Diagn. 2017;13(3):168–178.
   PubMed Web of Science ®Google Scholar
• Schuster RM, Cather C, Pachas GN, et al. Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. Addict Behav. 2017;71:89–95.
   PubMed Web of Science ®Google Scholar
• Evins A, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder a randomized clinical trial. JAMA. 2014;311:145–154.
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Garcia-Alvarez L, Sarramea F, et al. It is feasible and effective to help patients with severe mental disorders to quit smoking: an ecological pragmatic clinical trial with transdermal nicotine patches and varenicline. Schizophr Res. 2016;176(2–3):272–280.
   PubMed Web of Science ®Google Scholar
• Smith RC, Amiaz R, Si T-M, et al. Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PLoS One. 2016;11(1):e0143490.
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Yousefi MK, Kneeland RE, et al. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res. 2013;146(1–3):376–378.
   PubMed Web of Science ®Google Scholar
• Castle D, Baker AL, Richmond R, et al. Varenicline plus healthy lifestyle intervention for smoking cessation in psychotic disorders. Ann Clin Psychiatry. 2012;24(4):285–291.
   PubMed Web of Science ®Google Scholar
• Smith RC, Lindenmayer J-P, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110(1–3):149–155.
   PubMed Web of Science ®Google Scholar
• Weinberger AH, Hitsman B, Papandonatos GD, et al. Predictors of abstinence and changes in psychiatric symptoms in a pooled sample of smokers with schizophrenia receiving combination pharmacotherapy and behavioral therapy for smoking cessation. J Clin Psychopharmacol. 2009;29(6):601–603.
   PubMed Web of Science ®Google Scholar
• Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry. 2001;158(4):635–637.
   PubMed Web of Science ®Google Scholar
• Moss TG, Sacco KA, Allen TM, et al. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 2009;104(1–2):94–99.
   PubMed Web of Science ®Google Scholar
• FDA, U.F.a.D.A. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). 2009.
   Google Scholar
• Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28(2):99–112.
   PubMed Web of Science ®Google Scholar
• Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62(12):1049–1053.
   PubMed Web of Science ®Google Scholar
• Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469–494.
   PubMed Web of Science ®Google Scholar
• de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491–493.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121.
   PubMed Web of Science ®Google Scholar
• Cully M. Public health: the benefits and challenges of smoking cessation. Nat Rev Cardiol. 2013;10(3):117.
   PubMedGoogle Scholar
• Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2010;196(5):346–353.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Vancampfort D, Bobes J, et al. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand. 2015;132(2):122–130.
   PubMed Web of Science ®Google Scholar
• Shawen AE, Drayton SJ. Review of pharmacotherapy for smoking cessation in patients with schizophrenia. Ment Health Clin. 2018;8(2):78–85.
   PubMedGoogle Scholar
• Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2015;265(3):269-270.
   Web of Science ®Google Scholar
• Fiore  MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994;271(24):1940–1947.
   PubMed Web of Science ®Google Scholar
• Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1–245.
   Google Scholar
• Taylor DH Jr., Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990–996.
   PubMed Web of Science ®Google Scholar
• Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006;96(10):1808–1814.
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(7):765–772.
   PubMed Web of Science ®Google Scholar
• McRobbie H, Bullen, C., Hartmann‐Boyce, J., et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev. 2014;(12):CD010216.
   PubMed Web of Science ®Google Scholar
• Coles AS, Kozak K, George TP. A review of brain stimulation for treatment of substance use disorders. Am J Addict. 2018;27:71–91.
   PubMed Web of Science ®Google Scholar
• Wing VC, Wass CE, Bacher IC, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) reduces tobacco craving in smokers with schizophrenia. Schizophr Res. 2012;139:264–266.
   PubMed Web of Science ®Google Scholar
• Prikryl R, Ustohal L, Kucerova HP, et al. Repetitive transcranial magnetic stimulation reduces cigarette consumption in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2014;49:30–35.
   PubMed Web of Science ®Google Scholar
• Kozak K, Sharif-Razi M, Morozova M, et al. Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients with schizophrenia and non-psychiatric controls. Schizophr Res. 2018;197:441–443.
   PubMed Web of Science ®Google Scholar
• Smith RC, Boules S, Mattiuz S, et al. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study. Schizophr Res. 2015;168(1–2):260–266.
   PubMed Web of Science ®Google Scholar